Biogen (BIIB) Net Income - Minority (2009 - 2023)
Biogen (BIIB) posted quarterly Net Income - Minority of $4.1 million for Q3 2023, down 52.87% year-over-year from $8.7 million in Q3 2022, and down 35.94% on a QoQ basis from $6.4 million in Q2 2023.
Biogen (BIIB) Net Income - Minority (2009 - 2023) Analysis & Trends
Biogen (BIIB) has reported Net Income - Minority for 15 consecutive years, with $4.1 million the latest figure, recorded in Q3 2023.
- In Q3 2023, Net Income - Minority fell 52.87% year-over-year to $4.1 million; the TTM figure through Sep 2023 stood at $4.1 million (down 52.87% YoY), while the FY2022 annual figure was $9.5 million, up 114.96% from the prior year.
- Net Income - Minority came in at $4.1 million for Q3 2023 at Biogen, down from $6.4 million in the prior quarter.
- The five-year high for Net Income - Minority was $21.6 million in Q1 2022, with the low at -$462.9 million in Q2 2021.
- Average Net Income - Minority over 5 years is -$42.8 million, with a median of $8.7 million recorded in 2022.
- Across the five-year window, Net Income - Minority jumped 375.61% in 2020 and tumbled 3327.14% in 2021, its largest moves.
- Year by year, Net Income - Minority stood at $4.1 million in 2019, then soared by 246.34% to $14.2 million in 2020, then plunged by 547.18% to -$63.5 million in 2021, then soared by 114.96% to $9.5 million in 2022, then slumped by 56.84% to $4.1 million in 2023.
- According to Business Quant data, Net Income - Minority over the past three periods registered $4.1 million, $6.4 million, and $9.6 million for Q3 2023, Q2 2023, and Q1 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 4.10 Mn |
| Jun 30, 2023 | 6.40 Mn |
| Mar 31, 2023 | 9.60 Mn |
| Dec 31, 2022 | 9.50 Mn |
| Sep 30, 2022 | 8.70 Mn |
| Jun 30, 2022 | 9.10 Mn |
| Mar 31, 2022 | 21.60 Mn |
| Dec 31, 2021 | -63.50 Mn |
| Sep 30, 2021 | -451.80 Mn |
| Jun 30, 2021 | -462.90 Mn |
| Mar 31, 2021 | 19.00 Mn |
| Dec 31, 2020 | 14.20 Mn |
| Sep 30, 2020 | 14.00 Mn |
| Jun 30, 2020 | 19.50 Mn |
| Mar 31, 2020 | 10.00 Mn |
| Dec 31, 2019 | 4.10 Mn |
| Sep 30, 2019 | 4.10 Mn |
| Jun 30, 2019 | 4.10 Mn |
| Mar 31, 2019 | 7.90 Mn |
| Dec 31, 2018 | 8.00 Mn |